How durable is first-line ibrutinib-venetoclax in older CLL patients?

GLOW's 67-month follow-up shows fixed-duration ibrutinib-venetoclax keeps survival and treatment-free gains over chlorambucil-obinutuzumab.

Direct answer

In older or comorbid patients with previously untreated chronic lymphocytic leukemia (CLL), fixed-duration first-line ibrutinib-venetoclax remained more effective than chlorambucil-obinutuzumab at a median 67 months of follow-up: 66-month overall survival was 79.0% versus 60.8%, and 66-month progression-free survival was 51.7% versus 18.1%. The benefit persisted across IGHV and measurable residual disease (MRD) status, and patients on ibrutinib-venetoclax also gained 21.4 more months of progression-free time without grade 3/4 treatment-emergent adverse events.

1sources cited

This article was generated with WisPaper-powered search and paper analysis.

What the 67-month analysis measures

GLOW randomized 211 patients with previously untreated CLL 1:1 to fixed-duration ibrutinib-venetoclax (n = 106) or chlorambucil-obinutuzumab (n = 105). Most participants were 65 or older (184 patients, 87.2%), and 135 (64.0%) had a Cumulative Illness Rating Scale score above 6, so the trial population reflects the older and comorbid group the title asks about.

This report extends follow-up to a median of 67 months and adds a combined endpoint: grade 3/4 treatment-emergent adverse event (TEAE)-free progression-free survival. That endpoint counts time a patient spends both alive and progression-free and free of severe treatment-related side effects, so it captures treatment burden alongside disease control rather than efficacy alone.

Two details shape how the numbers should be read. Progression-free survival here is investigator-assessed, while the primary analysis used independent review. And because ibrutinib-venetoclax was given for a median of 13.8 months versus 5.1 months for chlorambucil-obinutuzumab, adverse events were collected over a longer exposure window for the ibrutinib-venetoclax arm.

Survival gap widens with mature follow-up

At 67 months, ibrutinib-venetoclax reduced the risk of death by 54% versus chlorambucil-obinutuzumab (hazard ratio 0.46, 95% CI 0.27–0.78; nominal p = 0.003). Estimated 66-month overall survival was 79.0% (95% CI 69.5–85.8%) with ibrutinib-venetoclax and 60.8% (95% CI 50.7–69.6%) with chlorambucil-obinutuzumab.

The overall survival curves are not the whole story. Earlier GLOW reports noted seven TEAE-related deaths in the ibrutinib-venetoclax group, four during the ibrutinib lead-in, all in patients who were frail or had elevated cardiovascular risk; two TEAE-related deaths occurred in the chlorambucil-obinutuzumab group. Those early deaths weighed on immature survival estimates, and the authors present the mature separation as evidence that the fixed-duration approach delivers durable benefit despite them.

Progression-free survival showed the same direction and a larger relative effect: 51.7% versus 18.1% at 66 months (hazard ratio 0.27, 95% CI 0.19–0.40; nominal p < 0.001). The authors also trace the PFS curve over time: 84% at 24 months, 75% at 42 months, and 52% at 66 months for ibrutinib-venetoclax.

Fewer patients need a second-line therapy

By 66 months, an estimated 19.3% of ibrutinib-venetoclax patients and 52.0% of chlorambucil-obinutuzumab patients had required second-line treatment, a 77% reduction in risk (hazard ratio 0.23, 95% CI 0.13–0.40; nominal p < 0.001) in an analysis censoring patients at death. Treatment-free survival, which counts next-line treatment or death as an event, was 65.7% versus 29.8% at 66 months (hazard ratio 0.34, 95% CI 0.22–0.51).

The IGHV split matters for interpretation. IGHV is the immunoglobulin heavy chain variable region gene; unmutated IGHV (uIGHV) is generally associated with worse outcomes. Among uIGHV patients, second-line treatment was needed by 20.7% on ibrutinib-venetoclax versus 68.1% on chlorambucil-obinutuzumab (hazard ratio 0.17, 95% CI 0.09–0.34). Among mutated IGHV (mIGHV) patients, few needed second-line therapy in either arm (19.7% versus 22.9%; hazard ratio 1.20, 95% CI 0.31–4.59; nominal p = 0.791), so the next-treatment advantage is concentrated in the uIGHV subgroup.

Retreatment after progression was feasible in both arms. Of 28 ibrutinib-venetoclax patients who progressed, 8 received single-agent ibrutinib, with a median response duration of 38.0 months (95% CI 14.6–54.2) among the 8; 3 received venetoclax-based treatment and 1 received zanubrutinib. In the chlorambucil-obinutuzumab arm, 31 of 46 treated progressors received single-agent ibrutinib, 7 acalabrutinib, and 12 venetoclax-based treatment.

MRD status splits PFS but not survival

MRD was measured in peripheral blood by next-generation sequencing, and undetectable MRD (uMRD) meant fewer than 1 CLL cell per 10,000 leukocytes (< 10⁻⁴) in patients who had at least a partial response. In a landmark analysis starting 54 months after end of treatment, ibrutinib-venetoclax patients with uMRD at end of treatment plus 3 months had 64% PFS (95% CI 45–78%; n = 58) versus 50% (95% CI 28–68%; n = 31) in those with detectable MRD.

The gap is widest within uIGHV: 54-month post-treatment PFS was 60% for uIGHV/uMRD (n = 40) and 28% for uIGHV/dMRD (n = 16). Patients with mIGHV maintained PFS regardless of MRD status (92% for mIGHV/uMRD, n = 13; 71% for mIGHV/dMRD, n = 14). The authors read this as evidence that MRD status is most informative in the uIGHV subgroup.

Overall survival did not follow the same split. In the ibrutinib-venetoclax arm, 54-month landmark overall survival was 85% (95% CI 72–92%) with uMRD and 93% (95% CI 75–98%) with detectable MRD. The paper's own framing is that disease control after fixed-duration treatment is durable even for patients who do not reach uMRD, so MRD should not be treated as a survival proxy in this dataset.

Counting time without severe adverse events

The grade 3/4 TEAE-free PFS analysis uses restricted mean survival time, which estimates the average number of months patients spend in a health state over the follow-up period rather than a single time-point percentage. Mean grade 3/4 TEAE-free PFS was 51.6 months for ibrutinib-venetoclax versus 30.2 months for chlorambucil-obinutuzumab, a difference of 21.4 months (95% CI 15.0–26.8; nominal p = 0.005).

The trade-off is visible in the toxicity state itself: mean time with grade 3/4 TEAEs was longer on ibrutinib-venetoclax, 1.9 versus 1.1 months (mean difference 0.9 months, 95% CI 0.4–1.3; nominal p = 0.0004). The authors attribute part of this to the longer treatment exposure and longer adverse-event collection window on the ibrutinib-venetoclax arm, which is why the combined endpoint, not the toxicity time alone, carries the interpretation.

Grade 5 TEAEs in the ibrutinib-venetoclax group were cardiac failure/pneumonia/sinus node dysfunction (n = 1), pneumonia/malignant neoplasm (n = 1), cardiac arrest (n = 1), ischemic stroke (n = 1), and sudden death (n = 2); in the chlorambucil-obinutuzumab group they were pneumonia (n = 1) and cholestasis (n = 1), all during the treatment phase. No additional grade 5 cardiac events were reported after treatment completion during extended follow-up, and second primary malignancies occurred in 13.2% of ibrutinib-venetoclax patients versus 17.1% of chlorambucil-obinutuzumab patients.

Where the comparator and design limit transfer

Chlorambucil-obinutuzumab was the standard first-line regimen for older or comorbid CLL patients when GLOW was designed, but the authors state it is no longer the preferred option. The trial therefore answers how durable ibrutinib-venetoclax is relative to that older backbone, not how it compares with current alternatives such as continuous BTK inhibitor monotherapy or other fixed-duration combinations.

The paper is explicit that cross-trial comparison is troublesome because populations, designs, follow-up duration, MRD methodology, and timing differ. It cites CLL17, where 3-year PFS was similar for fixed-duration ibrutinib-venetoclax, continuous ibrutinib, and venetoclax-obinutuzumab (79.4%, 81.0%, and 81.1%), and notes that head-to-head comparisons are lacking. GLOW was also not designed to compare cardiovascular toxicity between BTK inhibitors, so the cardiac findings describe ibrutinib-venetoclax in this population rather than a class-wide ranking.

The population boundary is equally concrete: 87.2% were 65 or older and 64.0% had a Cumulative Illness Rating Scale score above 6, so the results speak to older and/or comorbid patients rather than all-comers. The MRD analysis includes only next-generation sequencing results, and the post-treatment landmark analyses start from end of treatment, which means patients who progressed or died before that landmark are not represented in those percentages.

Why fixed-duration matters for the next decision

The most decision-relevant comparison in this paper is not simply that ibrutinib-venetoclax prolongs PFS. It is that a finite course produced 51.7% PFS and 79.0% overall survival at 66 months while leaving most patients without a second-line treatment, and did so with 21.4 more months of progression-free time free of grade 3/4 TEAEs. For an older or comorbid patient weighing continuous BTK inhibitor therapy against a time-limited combination, that combination of durability and treatment-free time is the paper's central claim.

The subgroup pattern sharpens the priority. The next-treatment benefit is concentrated in uIGHV patients (20.7% versus 68.1% needing second-line therapy), while mIGHV patients did well on either regimen. Within ibrutinib-venetoclax, uMRD at end of treatment plus 3 months identified better PFS, especially in uIGHV, but not better overall survival.

The authors' practical conclusion follows from those pieces: fixed-duration ibrutinib-venetoclax is an effective first-line option for older and/or comorbid CLL patients, with patient selection still shaped by ibrutinib's established cardiovascular toxicity profile. The cardiovascular signal in GLOW was confined to the treatment phase, which is consistent with the fixed-duration rationale, but the trial cannot establish that pattern against other BTK inhibitors.

Sources used in this answer

1

First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival

At 67-month median follow-up, fixed-duration ibrutinib-venetoclax maintained superior overall survival (66-month 79.0% vs 60.8%), progression-free survival (51.7% vs 18.1%), and reduced need for second-line therapy (19.3% vs 52.0%) versus chlorambucil-obinutuzumab in older/comorbid previously untreated CLL, with 21.4 more months of grade 3/4 TEAE-free PFS.